About E3 ubiquitin-protein ligase RNFT2
E3 ubiquitin-protein ligase RNFT2 (RNFT2) is a protein
from Homo sapiens identified by UniProt accession
Q96EX2, 444 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNFT2 |
| UniProt accession | Q96EX2 |
| Gene | RNFT2 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- protein measurement · score 0.22
- neuroticism measurement · score 0.18
- high density lipoprotein cholesterol measurement · score 0.14
- apolipoprotein A 1 measurement · score 0.14
- hippocampal volume · score 0.12
- gut microbiome measurement · score 0.11
- worry measurement · score 0.11
- brain volume measurement · score 0.10
- eosinophil count · score 0.08
- neuronal ceroid lipofuscinosis 1 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96EX2-F1 | alphafold | PREDICTED | 70.20 | — |
Amino-acid sequence (444 residues)
MWLFTVNQVL RKMQRRHSSN TDNIPPERNR SQALSSEASV DEGGVFESLK AEAASPPALF SGLSGSLPTS SFPSSLVLGS SAGGGDVFIQ MPASREEGGG RGEGGAYHHR QPHHHFHHGG HRGGSLLQHV GGDHRGHSEE GGDEQPGTPA PALSELKAVI CWLQKGLPFI LILLAKLCFQ HKLGIAVCIG MASTFAYANS TLREQVSLKE KRSVLVILWI LAFLAGNTLY VLYTFSSQQL YNSLIFLKPN LEMLDFFDLL WIVGIADFVL KYITIALKCL IVALPKIILA VKSKGKFYLV IEELSQLFRS LVPIQLWYKY IMGDDSSNSY FLGGVLIVLY SLCKSFDICG RVGGVRKALK LLCTSQNYGV RATGQQCTEA GDICAICQAE FREPLILLCQ HVFCEECLCL WLDRERTCPL CRSVAVDTLR CWKDGATSAH FQVY
Explore E3 ubiquitin-protein ligase RNFT2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets